2018 - 2021 Development of novel therapeutic strategy based on hemostatic characteristics of FVIII in the patients with moderate/mild hemophilia A
2017 - 2020 Studies on molecular pathology of hemophilia A and gain-of-function of FVIII
2015 - 2018 Basic research on establishment of a novel hemostatic treatment based on the hemostatic potential for mild hemophilia A with inhibitor
2013 - 2015 Basic reserch on hemostasis to establish a novel hemostatic therapy for hemophilia A patients with inhibitors
Papers (43)：
Koji Yada, Natsume Fujitate, Kenichi Ogiwara, Tetsuhiro Soeda, Takehisa Kitazawa, Keiji Nogami. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro. Thrombosis Research. 2024. in press
Yuya Mawarikado, Asuka Sakata, Yusuke Inagaki, Suguru Harada, Kohei Tatsumi, Naoki Matsumoto, Kenichi Ogiwara, Koji Yada, Yasushi Yoshimura, Akira Kido, et al. Force-sensing treadmill gait analysis system can detect gait abnormalities in haemophilia patients without arthropathy. Haemophilia : the official journal of the World Federation of Hemophilia. 2024
Koji Yada, Kenichi Ogiwara, Naruto Shimonishi, Yuto Nakajima, Tetsuhiro Soeda, Takehisa Kitazawa, Keiji Nogami. Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma. International journal of hematology. 2024. 119. 2. 109-118
Naruto Shimonishi, Kana Sasai, Kenichi Ogiwara, Shoko Furukawa, Yuto Nakajima, Kuniyoshi Mizumachi, Koji Yada, Masahiro Takeyama, Midori Shima, Narumi Mizuno, et al. Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis. International journal of hematology. 2023. 118. 6. 690-698
Masahiro Takeyama, Naoki Matsumoto, Hiroto Abe, Suguru Harada, Kenichi Ogiwara, Shoko Furukawa, Naruto Shimonishi, Yuto Nakajima, Koji Yada, Tetsuhiro Soeda, et al. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A. Pediatric blood & cancer. 2023. 70. 10. e30590
2014/12 - American Society of Hematology ASH Abstract Award Factor Va inactivation by activated protein C predominantly contributes to the downregulation of coagulation rather than factor VIIIa inactivation
2011/07 - International Society on Thrombosis and Haemostasis / The Japanese Society on Thrombosis and Hemostasis JSTH Asian-Pacific Scholarship Mild bleeding tendency in a severe hemophilia A with Arg1781His substitution associated with acceleration of factor Xa generation
2009/12 - American Society of Hematology Travel Award Effects of anti-factor VIII inhibitors on factor VIIa/tissue factor-catalyzed activation and inactivation of factor VIII
Show all
Association Membership(s) (5)：
Japanese Society for Genetic Counseling
, The Japanese Society on Thrombosis and Hemostasis
, Japanese Society of Hematology
, The Japanese Society of Pediatric Hematology / Oncology
, Japan Pediatric Society
